Compare SSBI & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | VRCA |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | 106 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.7M | 87.5M |
| IPO Year | N/A | 2018 |
| Metric | SSBI | VRCA |
|---|---|---|
| Price | $13.02 | $5.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 3.6K | ★ 119.7K |
| Earning Date | 04-28-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $103.06 |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $7.60 | $0.39 |
| 52 Week High | $14.00 | $9.82 |
| Indicator | SSBI | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 47.42 |
| Support Level | $12.73 | $5.18 |
| Resistance Level | $13.95 | $6.48 |
| Average True Range (ATR) | 0.25 | 0.52 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 32.53 | 55.77 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.